Winning Stocks Forecast: CUV.AX & YOW.AX bring highest returns from Australian stock market
Winning Stocks Forecast
Clinuvel Pharmaceuticals Limited (CUV.AX)
Source: biotech-capital.com
Over the past month Clinuvel Pharmaceuticals Limited (CUV.AX) saw a rise of 49.19% this marks it as the biggest earner within Australian Stock as I Know First predicted. This surge can be attributed to the anticipated FDA approval for its drug SCENESSE® a photo-protective drug used to treat a rare condition known as targeting erythropoietic protoporphyria (EPP). SCENESSE® is already approved by the EU in 2014 and was available from 2016 across Europe. In the first half of FY18, Clinuvel had revenue of just $7 million, enough to generate positive cash flows and NPAT of $1.4 million.
The calendar year 2018 has shown how all European and Swiss expert centres continue to prescribe SCENESSE® to their erythropoietic protoporphyria (EPP) patients, while this is driven purely by clinical demand without the Company actively promoting the drug or engaging in medical marketing campaigns. This approach provides clean analytical data to understand the percentage of patients requesting treatment year on year. The rate of continuation of EPP patients is higher than 95%, an unusual high percentage in ethical pharmaceuticals. Although this reception cannot always be expected in other markets it is nevertheless still a positive indicator as to the companies expected performance in a North American market.
Yowie Group Ltd (YOW.AX)
Source: fool.com.au
The second highest gainer of this month’s Australian stock forecast was Yowie Group Ltd with a 23.81% rise. The brand revolves around six Yowie characters that inspire a range of products that “promote learning, understanding and engagement with the natural world”. In January this year, Yowie cut its sales guidance for the 2018 financial year from 55% to 17% with its former North American chief Mark Schuessler taking over the reins from Mr Alfonso in a desperate bid to arrest company’s lagging sales and disappointing performance. However, under the new reigns things have picked up Yowie has recently partnered with The Los Angeles-based Davey, who is also chairman of Mel Gibson’s Icon Group, will be helping Yowie into publishing, film and animation and develop a series of short animations based on the Yowie characters.
The outlook for the 2019 financial year for YOW.AX is strong. With significant traction in distribution growth in North America and Australia it marks an unprecedented drive for the company towards profitability. With Yowie products still not distributed across over 50% of the North American market it presents a substantial penetration opportunity for the company. Yowie has recently undergone a remarkable stabilisation in the North American market paving the way for a dramatic increase in distribution.
This chart below shows the algorithmic forecast made on these 10 Australian stocks one month ago and the results of the forecast. As seen CUV.AX and YOW.AX where both included in the top ten stocks.
Current I Know First subscribers received these bullish forecasts for YOW.AX and CUV.AX on September 7th.
To subscribe today click here.
Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster.
Please note-for trading decisions use the most recent forecast.
About
Clinuvel Pharmaceuticals Limited (ASX: CUV) is a biopharmaceutical company. The Company is focused on developing drugs for the treatment of a range of severe skin disorders. Its lead compound, SCENESSE (afamelanotide 16 milligrams), prevents phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company focuses at preventing the symptoms of skin diseases related to the exposure to harmful ultra violet (UV) radiation and at repigmentation of the skin due to a number of depigmentation disorders. SCENESSE has completed Phase II and III trials in the United States and Europe and has been granted marketing authorization by the European Commission for adults with EPP. It has operations in Europe, the United States and Singapore. SCENESSE acts by increasing the levels of melanin in the skin and shields against UV radiation (UVR) and sunlight. SCENESSE is delivered via a subcutaneous dissolving implant
Yowie Group Ltd (ASX: YOW) is a global brand licensing company specialising in the development of consumer products designed to promote learning, understanding and engagement with the natural world through the adventures and exploits of six endearing Yowie characters. Educating children and adults about the environment and ecology is at the heart of the Yowie proposition. The Company’s vision for the Yowie brand includes distribution of Yowie product in North America, with further expansion planned into Australia, New Zealand and throughout Asia, where the Yowie brand is known and brand equity remains strong, even with the brand not having been active in the market for around eight years. Expansion into Europe and the Middle East are key strategic priorities for a second-stage brand rollout. Yowie Group Ltd was first listed on the Australian Securities Exchange in December 2012 under code name ‘YOW’. The Company’s registered head office is in Perth, Western Australia.
